Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. - Wikidata - awgldk - TriplyDB

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

http://www.wikidata.org/entity/Q39749438

about

Arresting serotonin Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders Aripiprazole: from pharmacological profile to clinical use Targeting G protein coupled receptor-related pathways as emerging molecular therapies DREADDs: novel tools for drug discovery and development Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Altered ratio of D1 and D2 dopamine receptors in mouse striatum is associated with behavioral sensitization to cocaine Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial.Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.Yokukansan and its ingredients as possible treatment options for schizophrenia.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy.The potential for selective pharmacological therapies through biased receptor signaling Discovery of GPCR ligands for probing signal transduction pathways.New functional activity of aripiprazole revealed: Robust antagonism of D2 dopamine receptor-stimulated Gβγ signaling Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Quetiapine and aripiprazole signal differently to ERK, p90RSK and c-Fos in mouse frontal cortex and striatum: role of the EGF receptor.CODA-RET reveals functional selectivity as a result of GPCR heteromerization.Pretreatment or Posttreatment with Aripiprazole Attenuates Methamphetamine-induced Stereotyped Behavior in Mice.Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.Effects of dopamine D2/D3 receptor ligands on food-cocaine choice in socially housed male cynomolgus monkeys.The role of kinetic context in apparent biased agonism at GPCRs.Aripiprazole acts as a selective dopamine D2 receptor partial agonist.Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics.GPCR functional selectivity has therapeutic impact.Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.Dopamine receptor homooligomers and heterooligomers in schizophrenia Pharmacological characterization of 2-methoxy-N-propylnorapomorphine's interactions with D2 and D3 dopamine receptors.Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein.A review of the safety and tolerability of aripiprazole.Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.G protein coupled receptors as allosteric proteins and the role of allosteric modulators.Pharmacokinetics and metabolism update for some recent antipsychotics.Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?Aripiprazole treatment for patients with schizophrenia: from acute treatment to maintenance treatment.Dopamine receptor signaling and current and future antipsychotic drugs.Biased agonism at G protein-coupled receptors: the promise and the challenges--a medicinal chemistry perspective.Exploiting agonist biased signaling of chemokines to target cancer.

P2860

Q24647492-C021FAED-B6AB-4A99-94A5-937E51C3B595 Q26748728-A2043C61-E83C-4367-91C6-BB4D33200039 Q26778312-F4F51E9A-345E-4AAD-A48A-0A3366E11C95 Q26829964-8A929D63-35EA-4B88-A72B-C97732CD4DDC Q26995396-8D263FC1-1CD0-4653-92F2-6B4DC2C499E8 Q28084069-482457FF-6A2D-45F2-BE5B-A82A66DB5C08 Q28474330-64A1C660-AA89-4B80-AD63-2A57EB5DF922 Q28546441-3AD01DEF-57F3-46B7-BD79-317408757578 Q30490025-B2F38370-9ED6-4F05-B17B-376FA3A49BC6 Q33890786-4E8ADCDC-219A-42EF-AF02-0B535F9FE0FE Q34011162-8EB9DE13-002A-4E04-A033-FF4C662C70D5 Q34140742-EAA7738C-A0CF-4258-A0C6-9BB406082FA6 Q34169978-1ED7D872-1341-4C47-B6AD-C729566824A1 Q34227284-D689F947-1174-4096-BC6C-907F26BCC74E Q34402658-3A92CAF5-9348-4438-8185-FFFA14233E3A Q34582707-9139A4AE-851C-4DFF-972D-058DE74CAF39 Q34772251-7A06A2A6-8334-4765-B849-AE795086F883 Q35012574-90CFD8BB-B2FE-409B-B8F5-8C22BFB99DCF Q35098192-570CA679-04DF-43E5-9260-A93ED423E732 Q35171170-F128C8EE-9A99-49FD-B5D3-BA922F988600 Q36216477-AB4A9B57-B529-48E8-8990-E20F5522C856 Q36237653-3C937903-0DD4-4D6C-98B9-A8534E2686C3 Q36573210-A94E8FE5-3666-4D61-A8AD-0FF13E654B77 Q36627558-6689254E-78C1-4C7B-8C9D-8114EA6F2DF7 Q36821350-0C341AD8-E25F-498A-A529-F66EBFC32D85 Q36870038-3AF58441-82CA-416D-9720-3E8688C3F83C Q36880909-FDCDA3FB-71B9-4D77-BB66-15DBD90B079F Q36972523-3FB94C06-9DBD-4EE2-8819-11F0433894BB Q37242424-52F3CA0E-A26E-4FDC-94E8-FEE23EB23474 Q37351558-DA87AEB7-64A5-42EB-AB6E-8C76C9EA88D3 Q37421226-C219EDE5-ADD2-4D2F-A601-5619102AA197 Q37510958-4D741F11-65DA-4FBB-B2B2-CE0D79524A95 Q37610141-C534032B-9DF4-4265-9A46-F6E42286AA7C Q37790693-59209058-2FC2-4085-A1CE-E5C00D6845EC Q37863118-D369D41A-E859-423A-8C74-7F0EC7BC0B98 Q37944127-DC8EC50F-FEFF-469B-9497-87125BE33297 Q37947687-A0673986-2977-4934-93FD-1291DC5C4D4D Q38058009-08137958-267B-4D43-B29A-5A56EE932594 Q38209355-F1EA8707-8250-4E89-93C8-90F94CF9E1D2 Q38819497-DF4651F9-4B5E-449B-A628-8ACE46F44018

P2860

Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.

http://www.wikidata.org/entity/Q39749438

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Aripiprazole has functionally ...... r-mediated signaling pathways.

@en

Aripiprazole has functionally ...... r-mediated signaling pathways.

@nl

type

label

Aripiprazole has functionally ...... r-mediated signaling pathways.

@en

Aripiprazole has functionally ...... r-mediated signaling pathways.

@nl

prefLabel

Aripiprazole has functionally ...... r-mediated signaling pathways.

@en

Aripiprazole has functionally ...... r-mediated signaling pathways.

@nl

P1433

Q39749438-2021A9EB-CAC8-4AD2-B60C-B48E4A6257FA

P1476

Q39749438-C36088DA-CC11-4EFC-8427-0A9BB3C142BA

P2093

Q39749438-CEDA29EA-3C88-4819-9F98-24A550C24B89

P2860

Q39749438-00DC200F-DDA2-4429-B677-03588EA64F61

Q39749438-0D4C2718-15E8-4DAF-9604-6DE58E858A82

Q39749438-105C9AC7-B712-4B4B-A4F2-C78DBFE90F37

Q39749438-12AC8EC7-83A6-4A30-8BE9-3A43EF006484

Q39749438-16BCCD90-E74F-4DB5-AFD1-1B43129554C7

Q39749438-287E181E-AF6D-4EC7-88A0-1400D400F48E

Q39749438-2DDD7FF9-9E59-48F8-8F99-526C00307475

Q39749438-3077CBC5-D179-4A69-98B6-935DCB11449C

Q39749438-5018248C-F46C-4A78-A6E8-EDF7F67D27A2

Q39749438-5274D8D3-4F9F-4C82-83CF-17F84C7F830B

P2888

Q39749438-1EEA0392-F283-41D8-97D8-F98D2DC595B7

P304

Q39749438-CE65C723-EAE8-42E1-A0FF-78088EEAA5E0

P31

Q39749438-C9A4F43C-147E-40E7-BA56-74D67107E1EB

P356

Q39749438-8C03B1E7-0098-4A8C-88EE-3EC731E00261

P407

Q39749438-DC7CC533-5129-404C-8780-5FD565AAD3BA

P433

Q39749438-50E72A11-B296-4A30-96A3-DCBF24A34E4D

P478

Q39749438-554DE211-25D9-4BE4-B029-AC6AE81998DB

P50

Q39749438-07F1A536-D547-44E4-BAB7-77E73BAD1A63

Q39749438-33DC434D-144F-4566-B537-3B5B7F1054AB

Q39749438-70548127-4E40-4111-A1CC-3B0D72970B01

P577

Q39749438-213DF82C-42B9-49C5-9A9A-C3531BFE213B

P5875

Q39749438-A3A38222-44E1-46C1-A738-1E8CB39B1088

P698

Q39749438-F66495E4-9463-4A03-9BB5-FF0E1E06ECC0

P921

Q39749438-a7dd86a1-e3ae-440b-b411-c741618c8bea

P356

P1433

Neuropsychopharmacology

P1476

Aripiprazole has functionally ...... or-mediated signaling pathways

@en

P2093

Gabriel A Vargas

http://www.w3.org/2001/XMLSchema#string

P2860

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase

Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs

Schizophrenic symptoms improve with apomorphine

Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

Alpha- and beta-adrenergic stimulation of arachidonic acid metabolism in cells in culture.

Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.

Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.

P2888

P304

67-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.NPP.1301071

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Richard Mailman

Jonathan D Urban

Mark von Zastrow

P577

2006-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7223966

http://www.w3.org/2001/XMLSchema#string

P698

16554739

http://www.w3.org/2001/XMLSchema#string

P921